Tetracosactide

Identification

Summary

Tetracosactide is a diagnostic agent used in the screening of patients presumed to have adrenocortical insufficiency.

Brand Names
Cortrosyn, Synacthen
Generic Name
Tetracosactide
DrugBank Accession Number
DB01284
Background

Tetracosactide (also known as Cosyntropin) is a synthetic peptide that is identical to the 24-amino acid segment (sequence: SYSMEHFRWGKPVGKKRRPVKVYP) at the N-terminal of adrenocorticotropic hormone. ACTH (1-24), a segment similar in all species, contains the biological activity that stimulates production of corticosteroids in the adrenal cortex. Tetracosactide exhibits the same activity as natural ACTH with regard to all its biological activities. The complex results in a product whose absorption in man is effected over a longer period of time as compared to corticotropin. Therefore, therapy may be maintained with less frequent administration.

Type
Small Molecule
Groups
Approved
Structure
Weight
Average: 2933.49
Monoisotopic: 2931.580641316
Chemical Formula
C136H210N40O31S
Synonyms
  • adrenocorticotropic hormone 1-24
  • Adrenocorticotropic hormone fragment 1-24 human, rat
  • alpha(1-24)-corticotrophin
  • ATCH (1-24)
  • beta(1-24)-corticotrophin
  • Corticotropin tetracosapeptide
  • corticotropin-(1-24)
  • corticotropin-(1-24) tetracosapeptide
  • Cosyntropin
  • Tetracosactida
  • Tetracosactide
  • Tetracosactrin
  • α1-24-corticotrophin
  • β1-24-corticotrophin

Pharmacology

Indication

For use as a diagnostic agent in the screening of patients presumed to have adrenocortical insufficiency.

Reduce drug development failure rates
Build, train, & validate machine-learning models
with evidence-based and structured datasets.
See how
Build, train, & validate predictive machine-learning models with structured datasets.
See how
Associated Conditions
Indication TypeIndicationCombined Product DetailsApproval LevelAge GroupPatient CharacteristicsDose Form
Adjunct therapy in treatment ofAcute gout••••••••••••
Management ofAcute rheumatic fever••••••••••••
Diagnostic agentAdrenal insufficiency••••••••••••
Management ofBell's palsy••••••••••••
Management ofChoroiditis••••••••••••
Contraindications & Blackbox Warnings
Prevent Adverse Drug Events Today
Tap into our Clinical API for life-saving information on contraindications & blackbox warnings, population restrictions, harmful risks, & more.
Learn more
Avoid life-threatening adverse drug events with our Clinical API
Learn more
Pharmacodynamics

Cosyntropin exhibits the full corticosteroidogenic activity of natural ACTH. Various studies have shown that the biologic activity of ACTH resides in the N- terminal portion of the molecule and that the 1-20 amino acid residue is the minimal sequence retaining full activity. Partial or complete loss of activity is noted with progressive shortening of the chain beyond 20 amino acid residue. For example, the decrement from 20 to 19 results in a 70% loss of potency. The pharmacologic profile of Cosyntropin is similar to that of purified natural ACTH. It has been established that 0.25 mg of Cosyntropin will stimulate the adrenal cortex maximally and to the same extent as 25 units of natural ACTH. Cosyntropin has less immunogenic activity than ACTH because the amino acid sequence having most of the antigenic activity of ACTH, i.e., amino acids 25-39, is not present in cosyntropin. The extra-adrenal effects which natural ACTH and Cosyntropin have in common include increased melanotropic activity, increased growth hormone secretion and an adipokinetic effect. These are considered to be without physiological or clinical significance.

Mechanism of action

Cosyntropin combines with a specific receptor in the adrenal cell plasma membrane and, in patients with normal adrenocortical function, stimulates the initial reaction involved in the synthesis of adrenal steroids (including cortisol, cortisone, weak androgenic substances, and a limited quantity of aldosterone) from cholesterol by increasing the quantity of the substrate within the mitochondria. Cosyntropin does not significantly increase plasma cortisol concentration in patients with primary or secondary adrenocortical insufficiency.

TargetActionsOrganism
AAdrenocorticotropic hormone receptor
agonist
Humans
Absorption

Rapidly absorbed following intramuscular administration.

Volume of distribution

Not Available

Protein binding

Not Available

Metabolism
Not Available
Route of elimination

Not Available

Half-life

About 15 minutes following intravenous administration.

Clearance

Not Available

Adverse Effects
Improve decision support & research outcomes
With structured adverse effects data, including: blackbox warnings, adverse reactions, warning & precautions, & incidence rates. View sample adverse effects data in our new Data Library!
See the data
Improve decision support & research outcomes with our structured adverse effects data.
See a data sample
Toxicity

Not Available

Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.
DrugInteraction
AcetazolamideThe risk or severity of liver damage can be increased when Tetracosactide is combined with Acetazolamide.
AmobarbitalThe risk or severity of liver damage can be increased when Tetracosactide is combined with Amobarbital.
BrexanoloneThe risk or severity of liver damage can be increased when Tetracosactide is combined with Brexanolone.
BrivaracetamThe risk or severity of liver damage can be increased when Tetracosactide is combined with Brivaracetam.
ButalbitalThe risk or severity of liver damage can be increased when Tetracosactide is combined with Butalbital.
Food Interactions
No interactions found.

Products

Drug product information from 10+ global regions
Our datasets provide approved product information including:
dosage, form, labeller, route of administration, and marketing period.
Access now
Access drug product information from over 10 global regions.
Access now
Product Ingredients
IngredientUNIICASInChI Key
Tetracosactide acetateH86HJ92K8Y22633-88-1DFABUZLKSKOWCS-WMPFGLIOSA-N
Brand Name Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing EndRegionImage
CortrosynInjection, powder, lyophilized, for solution0.25 mg/1mLIntramuscular; Intravenous; ParenteralHenry Schein, Inc.2022-01-09Not applicableUS flag
CortrosynInjection, powder, lyophilized, for solution0.25 mg/1mLIntramuscular; Intravenous; ParenteralGeneral Injectables & Vaccines, Inc2010-03-01Not applicableUS flag
CortrosynInjection, powder, lyophilized, for solution0.25 mg/1mLIntramuscular; IntravenousA-S Medication Solutions2003-08-01Not applicableUS flag
CortrosynInjection, powder, lyophilized, for solution0.25 mg/1mLIntramuscular; IntravenousAmphastar Pharmaceuticals, Inc.2003-08-01Not applicableUS flag
Cortrosyn Inj 0.25mgPowder, for solution0.25 mg / vialIntramuscular; IntravenousAmphastar Pharmaceuticals, Inc.1974-12-31Not applicableCanada flag
Generic Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing EndRegionImage
CosyntropinInjection, powder, lyophilized, for solution0.25 mg/1mLIntravenousSandoz Inc2012-06-29Not applicableUS flag
CosyntropinInjection, powder, lyophilized, for solution0.25 mg/1mLIntramuscular; IntravenousGeneraMedix2009-12-182013-02-08US flag
CosyntropinInjection, powder, lyophilized, for solution0.25 mg/1mLIntravenousMedical Purchasing Solutions, Llc2012-06-29Not applicableUS flag
CosyntropinInjection, powder, for solution0.25 mg/1mLIntramuscular; IntravenousMylan Institutional LLC2013-04-24Not applicableUS flag
CosyntropinInjection, powder, lyophilized, for solution0.25 mg/1mLIntravenousHF Acquisition Co LLC, DBA HealthFirst2021-07-10Not applicableUS flag

Categories

ATC Codes
H01AA02 — Tetracosactide
Drug Categories
Chemical TaxonomyProvided by Classyfire
Description
This compound belongs to the class of organic compounds known as polypeptides. These are peptides containing ten or more amino acid residues.
Kingdom
Organic compounds
Super Class
Organic Polymers
Class
Polypeptides
Sub Class
Not Available
Direct Parent
Polypeptides
Alternative Parents
Peptides / Tyrosine and derivatives / Arginine and derivatives / Phenylalanine and derivatives / Histidine and derivatives / Glutamic acid and derivatives / Methionine and derivatives / Valine and derivatives / Proline and derivatives / N-acyl-L-alpha-amino acids
show 30 more
Substituents
1-hydroxy-2-unsubstituted benzenoid / 3-alkylindole / Alcohol / Alpha peptide / Alpha-amino acid amide / Alpha-amino acid or derivatives / Amine / Amino acid / Amino acid or derivatives / Amphetamine or derivatives
show 61 more
Molecular Framework
Aromatic heteropolycyclic compounds
External Descriptors
polypeptide (CHEBI:3901)
Affected organisms
  • Humans and other mammals

Chemical Identifiers

UNII
72YY86EA29
CAS number
16960-16-0
InChI Key
ZOEFCCMDUURGSE-SQKVDDBVSA-N
InChI
InChI=1S/C136H210N40O31S/c1-75(2)109(127(200)154-71-106(181)156-88(31-13-17-52-137)114(187)158-89(32-14-18-53-138)115(188)159-91(35-21-56-149-134(142)143)116(189)164-96(37-23-58-151-136(146)147)131(204)175-60-25-39-104(175)126(199)173-111(77(5)6)128(201)163-90(33-15-19-54-139)120(193)171-110(76(3)4)129(202)169-101(65-80-43-47-84(180)48-44-80)132(205)176-61-26-40-105(176)133(206)207)172-125(198)103-38-24-59-174(103)130(203)95(34-16-20-55-140)157-107(182)70-153-113(186)99(66-81-68-152-87-30-12-11-29-85(81)87)167-117(190)92(36-22-57-150-135(144)145)160-121(194)98(63-78-27-9-8-10-28-78)166-123(196)100(67-82-69-148-74-155-82)168-118(191)93(49-50-108(183)184)161-119(192)94(51-62-208-7)162-124(197)102(73-178)170-122(195)97(165-112(185)86(141)72-177)64-79-41-45-83(179)46-42-79/h8-12,27-30,41-48,68-69,74-77,86,88-105,109-111,152,177-180H,13-26,31-40,49-67,70-73,137-141H2,1-7H3,(H,148,155)(H,153,186)(H,154,200)(H,156,181)(H,157,182)(H,158,187)(H,159,188)(H,160,194)(H,161,192)(H,162,197)(H,163,201)(H,164,189)(H,165,185)(H,166,196)(H,167,190)(H,168,191)(H,169,202)(H,170,195)(H,171,193)(H,172,198)(H,173,199)(H,183,184)(H,206,207)(H4,142,143,149)(H4,144,145,150)(H4,146,147,151)/t86-,88-,89-,90-,91-,92-,93-,94-,95-,96-,97-,98-,99-,100-,101-,102-,103-,104-,105-,109-,110-,111-/m0/s1
IUPAC Name
(2S)-1-[(2S)-2-[(2S)-2-[(2S)-6-amino-2-[(2S)-2-{[(2S)-1-[(2S)-2-[(2S)-2-[(2S)-6-amino-2-[(2S)-6-amino-2-{2-[(2S)-2-{[(2S)-1-[(2S)-6-amino-2-{2-[(2S)-2-[(2S)-2-[(2S)-2-[(2S)-2-[(2S)-2-[(2S)-2-[(2S)-2-[(2S)-2-[(2S)-2-amino-3-hydroxypropanamido]-3-(4-hydroxyphenyl)propanamido]-3-hydroxypropanamido]-4-(methylsulfanyl)butanamido]-4-carboxybutanamido]-3-(1H-imidazol-5-yl)propanamido]-3-phenylpropanamido]-5-carbamimidamidopentanamido]-3-(1H-indol-3-yl)propanamido]acetamido}hexanoyl]pyrrolidin-2-yl]formamido}-3-methylbutanamido]acetamido}hexanamido]hexanamido]-5-carbamimidamidopentanamido]-5-carbamimidamidopentanoyl]pyrrolidin-2-yl]formamido}-3-methylbutanamido]hexanamido]-3-methylbutanamido]-3-(4-hydroxyphenyl)propanoyl]pyrrolidine-2-carboxylic acid
SMILES
CSCC[C@H](NC(=O)[C@H](CO)NC(=O)[C@H](CC1=CC=C(O)C=C1)NC(=O)[C@@H](N)CO)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC1=CN=CN1)C(=O)N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC1=CNC2=C1C=CC=C2)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N1CCC[C@H]1C(=O)N[C@@H](C(C)C)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N1CCC[C@H]1C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC1=CC=C(O)C=C1)C(=O)N1CCC[C@H]1C(O)=O

References

General References
Not Available
KEGG Drug
D00284
KEGG Compound
C06926
PubChem Compound
16133751
PubChem Substance
46506301
ChemSpider
10481947
BindingDB
50017180
RxNav
2890
ChEBI
3901
ChEMBL
CHEMBL2103784
Therapeutic Targets Database
DAP000284
PharmGKB
PA164749052
RxList
RxList Drug Page
Drugs.com
Drugs.com Drug Page
Wikipedia
Adrenocorticotropic_hormone_(medication)

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
4CompletedDiagnosticAdrenal Insufficiency / Healthy Volunteers (HV) / Hypopituitarism1
4CompletedTreatmentAdrenal Failure1
4CompletedTreatmentPostdural Puncture Headache1
4Unknown StatusDiagnosticPrimary Aldosteronism1
4WithdrawnDiagnosticAdrenal Insufficiency1

Pharmacoeconomics

Manufacturers
Not Available
Packagers
  • Amphastar Pharmaceuticals
  • Generamedix Inc.
  • Sandoz
Dosage Forms
FormRouteStrength
Injection, powder, lyophilized, for solutionIntramuscular; Intravenous; Parenteral0.25 mg/1mL
Powder, for solutionIntramuscular; Intravenous0.25 mg / vial
Injection, powder, for solutionIntramuscular; Intravenous0.25 mg/1mL
Injection, powder, lyophilized, for solutionIntramuscular; Intravenous0.25 mg/1mL
Injection, powder, lyophilized, for solutionIntravenous0.25 mg/1mL
Injection, solutionIntravenous0.25 mg/1mL
Injection, solutionIntravenous
Injection, suspensionIntramuscular1 MG/ML
SolutionIntramuscular; Intravenous0.25 mg/1ml
SuspensionIntramuscular1 mg / mL
Injection, suspensionIntramuscular1 mg
Prices
Unit descriptionCostUnit
Cortrosyn 0.25 mg vial127.9USD vial
Cosyntropin 0.25 mg/ml119.91USD ml
Cosyntropin 0.25 mg vial115.1USD vial
Synacthen Depot 1 mg/vial34.77USD vial
DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.
Patents
Not Available

Properties

State
Solid
Experimental Properties
Not Available
Predicted Properties
PropertyValueSource
Water Solubility0.0481 mg/mLALOGPS
logP-0.95ALOGPS
logP-14Chemaxon
logS-4.8ALOGPS
pKa (Strongest Acidic)3.03Chemaxon
pKa (Strongest Basic)12.38Chemaxon
Physiological Charge6Chemaxon
Hydrogen Acceptor Count46Chemaxon
Hydrogen Donor Count42Chemaxon
Polar Surface Area1158.72 Å2Chemaxon
Rotatable Bond Count93Chemaxon
Refractivity790.98 m3·mol-1Chemaxon
Polarizability309.35 Å3Chemaxon
Number of Rings9Chemaxon
Bioavailability0Chemaxon
Rule of FiveNoChemaxon
Ghose FilterNoChemaxon
Veber's RuleNoChemaxon
MDDR-like RuleYesChemaxon
Predicted ADMET Features
Not Available

Spectra

Mass Spec (NIST)
Not Available
Spectra
Not Available
Chromatographic Properties
Collision Cross Sections (CCS)
Not Available

Targets

Build, predict & validate machine-learning models
Use our structured and evidence-based datasets to unlock new
insights and accelerate drug research.
Learn more
Use our structured and evidence-based datasets to unlock new insights and accelerate drug research.
Learn more
Kind
Protein
Organism
Humans
Pharmacological action
Yes
Actions
Agonist
General Function
Melanocortin receptor activity
Specific Function
Receptor for corticotropin (ACTH). This receptor is mediated by G proteins (G(s)) which activate adenylate cyclase (cAMP).
Gene Name
MC2R
Uniprot ID
Q01718
Uniprot Name
Adrenocorticotropic hormone receptor
Molecular Weight
33926.28 Da
References
  1. Schwerin M, Kanitz E, Tuchscherer M, Brussow KP, Nurnberg G, Otten W: Stress-related gene expression in brain and adrenal gland of porcine fetuses and neonates. Theriogenology. 2005 Mar 1;63(4):1220-34. [Article]
  2. Mehrabani PA, Bassett JR: Adrenocorticotropin binding sites in rat cardiac tissue. Pharmacol Biochem Behav. 1990 Jan;35(1):99-103. [Article]
  3. Moraes RB, Czepielewski MA, Friedman G: Cortisol variation after low-dose Cortrosyn test. Crit Care Med. 2010 Jul;38(7):1612-3. doi: 10.1097/CCM.0b013e3181da4ef1. [Article]
  4. Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. [Article]

Drug created at May 24, 2007 03:46 / Updated at March 19, 2024 11:06